Hikma Pharmaceuticals Launches Caffeine Citrate Injection, Commercialising The First Of The Bedford Products
London, 12 May 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has launched CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL). CAFCIT® is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.
Said Darwazah, Chairman and CEO of Hikma said, "This is our first launch from the Bedford portfolio acquired last year. We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."
According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.
-- ENDS --
Enquiries Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager
+44 (0)20 7399 2768/ +44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.
Help employers find you! Check out all the jobs and post your resume.
Said Darwazah, Chairman and CEO of Hikma said, "This is our first launch from the Bedford portfolio acquired last year. We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."
According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.
-- ENDS --
Enquiries Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager
+44 (0)20 7399 2768/ +44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.
Help employers find you! Check out all the jobs and post your resume.